Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 14/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1878978 | 0.76 | MEN1 (0.38) | TSHRALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL11337639 | 0.71 | KMT2A (0.44) | TSHRALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL96984 | 0.63 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL12798235 | 0.61 | — | — | |
| SCHEMBL12111894 | 0.61 | — | — | |
| SCHEMBL9089789 | 0.59 | — | — | |
| SCHEMBL3015911 | 0.58 | SLC9A1 (0.36) | ALDH1A1MEN1KMT2A | |
| SCHEMBL1544451 | 0.55 | MAPT (0.49) | TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL1610603 | 0.55 | — | — | |
| SCHEMBL5537061 | 0.54 | SLC6A4 (0.44) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960422-B2 | Pharmaceutically active compounds containing tetrazolyl and triazolyl rings | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| EP-2231647-A1 | TETRAZOLE DERIVATES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS (MGLURS) | AstraZeneca AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20090131454-A1 | New compounds 067 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| WO-2009051556-A1 | TETRAZOLE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS (MGLURS) | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131454-A1 | New compounds 067 | UGT2B7, UGT1A7, CYP3A7 | TSHR 3823/4885ALDH1A1 1808/4885TDP1 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.